FDA recall record

Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle recall — FDA D-0432-2017

Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules

Class IIIclassification
D-0432-2017official record ID
Jan 25, 2017report date

Recall record at a glance

Official recordD-0432-2017
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmShire PLC
Report dateJan 25, 2017
Recall initiation dateDec 2, 2016
Quantity4,520 bottles
LocationLexington, MA, United States

Official product description

Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81

Why the product was recalled

Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules

Distribution information

Nationwide and Puerto Rico

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: not stated.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.